140 related articles for article (PubMed ID: 38069817)
1. AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell Selectivity.
Liang Y; An Q; Song H; Tang Y; Xiao S; Wu J; Yan N; Yu B; Cao X; Lu M
J Med Chem; 2023 Dec; 66(24):16579-16596. PubMed ID: 38069817
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
Yoda A; Toyoshima K; Watanabe Y; Onishi N; Hazaka Y; Tsukuda Y; Tsukada J; Kondo T; Tanaka Y; Minami Y
J Biol Chem; 2008 Jul; 283(27):18969-79. PubMed ID: 18482988
[TBL] [Abstract][Full Text] [Related]
3. ATR, PML, and CHK2 play a role in arsenic trioxide-induced apoptosis.
Joe Y; Jeong JH; Yang S; Kang H; Motoyama N; Pandolfi PP; Chung JH; Kim MK
J Biol Chem; 2006 Sep; 281(39):28764-71. PubMed ID: 16891316
[TBL] [Abstract][Full Text] [Related]
4. Gelling Bodies: Understanding the Mechanisms Underlying Arsenic Trioxide Action.
Salomoni P
Cancer Discov; 2023 Dec; 13(12):2505-2506. PubMed ID: 38084094
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.
Liu Q; Hilsenbeck S; Gazitt Y
Blood; 2003 May; 101(10):4078-87. PubMed ID: 12531793
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
Wang ZG; Rivi R; Delva L; König A; Scheinberg DA; Gambacorti-Passerini C; Gabrilove JL; Warrell RP; Pandolfi PP
Blood; 1998 Sep; 92(5):1497-504. PubMed ID: 9716575
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53.
Akay C; Gazitt Y
Cell Cycle; 2003; 2(4):358-68. PubMed ID: 12851490
[TBL] [Abstract][Full Text] [Related]
8. Molecular targets of arsenic trioxide in malignant cells.
Miller WH
Oncologist; 2002; 7 Suppl 1():14-9. PubMed ID: 11961205
[TBL] [Abstract][Full Text] [Related]
9. Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
Balasundaram N; Ganesan S; Chendamarai E; Palani HK; Venkatraman A; Alex AA; David S; Kumar SP; Radhakrishnan NR; Yasar M; Krishna S; Korula A; Kulkarni U; Janet NB; Balasubramanian P; Mathews V
Blood Adv; 2022 Jan; 6(2):652-663. PubMed ID: 34625794
[TBL] [Abstract][Full Text] [Related]
10. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
11. Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site.
Chen S; Wu JL; Liang Y; Tang YG; Song HX; Wu LL; Xing YF; Yan N; Li YT; Wang ZY; Xiao SJ; Lu X; Chen SJ; Lu M
Cancer Cell; 2021 Feb; 39(2):225-239.e8. PubMed ID: 33357454
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression.
Yan W; Zhang Y; Zhang J; Liu S; Cho SJ; Chen X
J Biol Chem; 2011 May; 286(20):17478-86. PubMed ID: 21454520
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
Li Y; Qu X; Qu J; Zhang Y; Liu J; Teng Y; Hu X; Hou K; Liu Y
Cancer Lett; 2009 Nov; 284(2):208-15. PubMed ID: 19457607
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic effects of arsenic trioxide on acute promyelocytic leukemia and other types of leukemias.
Yousefnia S
Cell Biol Int; 2021 Jun; 45(6):1148-1157. PubMed ID: 33527587
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53: MAP kinase pathway is preferentially activated in cells expressing inactivated p53.
Kircelli F; Akay C; Gazitt Y
Int J Oncol; 2007 Apr; 30(4):993-1001. PubMed ID: 17332940
[TBL] [Abstract][Full Text] [Related]
16. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide: an anti cancer missile with multiple warheads.
Gazitt Y; Akay C
Hematology; 2005 Jun; 10(3):205-13. PubMed ID: 16019469
[TBL] [Abstract][Full Text] [Related]
18. TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells.
Wang H; Wang X; Xu L; Zhang J
FEBS Open Bio; 2022 Mar; 12(3):616-626. PubMed ID: 35030298
[TBL] [Abstract][Full Text] [Related]
19. MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells.
Golemovic M; Quintás-Cardama A; Manshouri T; Orsolic N; Duzkale H; Johansen M; Freireich EJ; Kantarjian H; Zingaro RA; Verstovsek S
Invest New Drugs; 2010 Aug; 28(4):402-12. PubMed ID: 19468689
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide reduces the expression of E2F1, cyclin E, and phosphorylation of PI3K signaling molecules in acute leukemia cells.
Kumar S; Tchounwou PB
Environ Toxicol; 2021 Sep; 36(9):1785-1792. PubMed ID: 34042274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
